VI

VIVOZON PHARMACEUTICAL CO., LTD.

Develops multi-target drugs for pain and central nervous system (CNS) diseases.

082800 | KO

Overview

Corporate Details

ISIN(s):
KR7082800004
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 제약공단2길 34-40, 화성시

Description

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2022-03-25 00:00
주요사항보고서(타법인주식및출자증권양수결정)
Korean HTML 20.9 KB
2022-03-25 00:00
단기차입금증가결정
Korean HTML 9.3 KB
2022-03-25 00:00
주요사항보고서(유상증자결정)
Korean HTML 29.1 KB
2022-03-22 00:00
감사보고서제출
Korean HTML 24.4 KB
2022-03-22 00:00
사업보고서 (2021.12)
Korean HTML 726.9 KB
2022-03-18 00:00
[기재정정]주주총회소집공고
Korean HTML 199.4 KB
2022-03-18 00:00
[기재정정]의결권대리행사권유참고서류
Korean HTML 181.4 KB
2022-03-15 00:00
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Korean HTML 19.3 KB
2022-03-15 00:00
주주총회소집결의
Korean HTML 7.6 KB
2022-03-15 00:00
주주총회집중일개최사유신고
Korean HTML 4.7 KB
2022-03-15 00:00
주주총회소집공고
Korean HTML 190.6 KB
2022-03-15 00:00
의결권대리행사권유참고서류
Korean HTML 172.4 KB
2022-03-02 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean HTML 11.4 KB
2022-02-25 00:00
수시공시의무관련사항(공정공시)(코로나19 검체수송배지 등 공급계약 건)
Korean HTML 6.3 KB
2022-02-17 00:00
전환가액의조정(제19차)
Korean HTML 10.5 KB

Automate Your Workflow. Get a real-time feed of all VIVOZON PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for VIVOZON PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for VIVOZON PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.